DDrare: Database of Drug Development for Rare Diseases

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione; AB1010; ABBV-8E12; AL; AL-108; ASK Nr. 21972; AZP2006 oral solution; Alpha-lipoic acid and L-acetyl carnitine; Anti-Parkinson medication; Antisense oligonucleotide; Azilect; BIIB092; BMS-986168; BMS986168; BOTULINUM TOXIN TYPE A; Balance; Bepranemab; Botulinum toxin type A; Carnitine; CoQ10; Coenzym Q10 Nanodispersion; Coenzym Q10, Ubiquinon, Ubichinon; Coenzyme Q10; Creatine; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Donepezil; Droxidopa; Emeramide; Exelon 1,5 mg Hartkapseln; Exelon 3,0 mg Hartkapseln; Exelon 6,0 mg Hartkapseln; F-18; F-18 AV 1451; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Fresh Frozen Plasma; GDNF & Synchro Med Infusion System; Gold; Hydrogen; Leucine; Lipoic acid; Lithium; MASITINIB MESYLATE; Masitinib; Masitinib 100mg; Masitinib 200mg; Masitinib mesylate; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NP031112; NP031112 600mg; NP031112 800mg; NT 101; Niacinamide; Nitrogen; Other: 13C6 Leucine; Placebo; Procedure: Brain PET scan; Pyruvate, creatine, niacinamide; RASAGILINE MESILATE; RIVASTIGMINE; Raclopride; Radiopharmaceuticals; Rasagilin; Rasagiline; Riluzole; Rivastigmine; Salsalate; Single dose C2N-8E12; Stem cell therapy; Sugar pill; Suvorexant; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Tideglusib; Tolfenamic Acid; Tolfenamic acid; Trihexyphenidyl; UCB0107 (bepranemab); Ubidecarenon; Valproic acid; Vizamyl; Vizamyl (flutemetamol(F-18)); Water; Xeomin; Zolpidem; [18F]Florbetapir; [18F]MNI-815 (MNI-815); [18F]MNI-952; [18F]MNI-958; [18F]T807 ([18F]MNI-777); [F18]-FDDNP

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-019159-23-GB (EUCTR)	22/12/2010	08/10/2010	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.	Progressive Supranuclear Palsy MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Allon Therapeutics Inc	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 2;Phase 3	France;United States;Canada;Australia;Germany;United Kingdom
2	EUCTR2010-019159-23-DE (EUCTR)	08/11/2010	27/08/2010	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.	A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.	Progressive Supranuclear Palsy MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Davunetide Product Code: AL -108 INN or Proposed INN: Davunetide	Allon Therapeutics Inc	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 2;Phase 3	France;United States;Canada;Australia;Germany;United Kingdom
3	NCT01110720 (ClinicalTrials.gov)	October 2010	23/4/2010	Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy	Progressive Supranuclear Palsy	Drug: Davunetide;Drug: Placebo	Allon Therapeutics	NULL	Completed	41 Years	85 Years	Both	313	Phase 2;Phase 3	United States;Australia;Canada;France;Germany;United Kingdom
4	NCT01056965 (ClinicalTrials.gov)	January 2010	21/1/2010	Davunetide (AL-108) in Predicted Tauopathies - Pilot Study	A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies	Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia	Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray	University of California, San Francisco	NULL	Completed	40 Years	85 Years	All	12	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2010-019159-23-GB
(EUCTR)

22/12/2010

08/10/2010

A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.

Progressive Supranuclear Palsy
MedDRA version: 14.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Allon Therapeutics Inc

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 2;Phase 3

France;United States;Canada;Australia;Germany;United Kingdom

EUCTR2010-019159-23-DE
(EUCTR)

08/11/2010

27/08/2010

A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.

Progressive Supranuclear Palsy
MedDRA version: 14.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: Davunetide
Product Code: AL -108
INN or Proposed INN: Davunetide

Allon Therapeutics Inc

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 2;Phase 3

France;United States;Canada;Australia;Germany;United Kingdom

NCT01110720
(ClinicalTrials.gov)

October 2010

23/4/2010

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Progressive Supranuclear Palsy

Drug: Davunetide;Drug: Placebo

Allon Therapeutics

NULL

Completed

41 Years

85 Years

Both

313

Phase 2;Phase 3

United States;Australia;Canada;France;Germany;United Kingdom

NCT01056965
(ClinicalTrials.gov)

January 2010

21/1/2010

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies

Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia

Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray

University of California, San Francisco

NULL

Completed

40 Years

85 Years

All

Phase 1

United States